Pregnant women, breathe easy: a groundbreaking study debunks the myth linking paracetamol to autism. But here's where it gets controversial: despite former President Donald Trump’s alarming claims urging women to avoid this common painkiller during pregnancy, a major international study has found no evidence to support his assertions. This comprehensive research, published in The Lancet Obstetrics, Gynaecology and Women’s Health, analyzed data from over 1 million children and concluded that paracetamol does not increase the risk of autism, ADHD, or intellectual disabilities. And this is the part most people miss: the study’s strength lies in its meticulous sibling comparison method, which minimizes external variables like genetics and environment, providing a more reliable analysis.
The controversy began in September when Trump advised pregnant women to ‘tough it out’ rather than take paracetamol, sparking global criticism from scientists. The new study, which reviewed 43 rigorous studies involving 262,852 children assessed for autism, 335,255 for ADHD, and 406,681 for intellectual disability, aimed to address these claims once and for all. Lead author Prof Asma Khalil reassured expectant mothers, stating, ‘Paracetamol remains a safe option during pregnancy when taken as guided.’
But is the debate truly over? While the study’s findings are robust, some may argue that the focus on paracetamol distracts from other potential maternal factors, such as the underlying pain or fever that prompts its use. Researchers suggest these conditions, rather than the medication itself, could be linked to developmental outcomes. This raises a thought-provoking question: Are we too quick to blame medications without fully understanding the broader context?
The study also highlights the limitations of earlier research, much of which relied on self-reported data and failed to control for confounding factors like genetics and environmental influences. Dr. Steven Kapp points out that neuro-divergences often run in families, meaning parents of disabled children might take paracetamol more frequently due to their own chronic conditions, not because the medication causes their child’s disability. As a neuro-divergent advocate, Kapp challenges society to shift its focus from ‘false prevention’ to creating a more inclusive world for disabled individuals.
So, where do you stand? Do you believe this study puts the paracetamol debate to rest, or is there still room for skepticism? Share your thoughts in the comments—let’s keep the conversation going.
